Results 1 to 10 of about 6,509 (259)

Disproportionality analysis of drug-induced dry mouth using data from the United States food and drug administration adverse event reporting system database

open access: yesHeliyon
Background: Drug-induced dry mouth is an adverse reaction that can significantly affect the quality of life and mental state of patients. In this study, we aimed to identify the most common drugs associated with dry mouth using data from the United ...
Dan Xu, Hong Zhu, Meng Wu
doaj   +1 more source

Comparative safety profile of biktarvy: insights from a clinical cohort and the FAERS database

open access: yesFrontiers in Pharmacology
BackgroundBiktarvy, a second-generation integrase strand-transfer inhibitor, is approved for treating human immunodeficiency virus (HIV) in patients with no known resistance to its components.
Xinmei Pan   +4 more
doaj   +1 more source

Drug-associated congenital anomalies of the external ear identified in the United States food and drug administration adverse event reporting system database

open access: yesScientific Reports
Congenital anomalies of the external ear can have a significant impact on a child’s development and quality of life. While genetic factors play a crucial role in the etiology of these anomalies, environmental factors such as drug exposure during ...
Xinyu Li   +3 more
doaj   +1 more source

Neurological Adverse Events Associated with the Use of Janus Kinase Inhibitors: A Pharmacovigilance Study Based on Vigibase

open access: yesPharmaceuticals
Background: Janus kinase (JAK) inhibitors are a new class of targeted therapies that block cytokines and the signal transduction and activators of transcription (STAT) pathway.
Sunny Park   +5 more
doaj   +1 more source

FAERS-based pharmacovigilance study of sevoflurane-associated adverse events: A 20-year comprehensive analysis

open access: yesPakistan Journal of Pharmaceutical Sciences
Background: Sevoflurane, an ether-derived inhalational anesthetic widely used for general anesthesia, requires comprehensive safety evaluation. Objectives: This study aimed to identify sevoflurane-associated adverse events and detect unexpected safety ...
Jieyuan Chen, Zhaojun Wang, Songsong Mao
doaj   +1 more source

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system

open access: yesFrontiers in Oncology
BackgroundRipretinib has been approved for the treatment of gastrointestinal stromal tumors (GIST). As a novel therapy, several adverse reactions remain unidentified, necessitating a thorough safety evaluation.
Sentai Wang   +4 more
doaj   +1 more source

Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis

open access: yesBMC Cardiovascular Disorders
Background Mavacamten is a novel selective cardiac myosin inhibitor indicated for patients with obstructive hypertrophic cardiomyopathy (oHCM). Given its negative inotropic properties, which theoretically reduce myocardial contractility and affect left ...
Lingqing Ding   +4 more
doaj   +1 more source

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database

open access: yesFrontiers in Oncology
IntroductionPacritinib, a selective Janus kinase (JAK) inhibitor, is approved for the treatment of myelofibrosis in adults with severe thrombocytopenia. However, its safety profile in real-world populations remains unclear. The aim of study is provided a
Huiling Zhang   +4 more
doaj   +1 more source

Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data

open access: yesScientific Reports
Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. This study aimed to
Wei Jia, Tiezhou Wang
doaj   +1 more source

Home - About - Disclaimer - Privacy